Germany’s Critical Shortage of Life-Saving Antibiotics Sparks Emergency Measures

Germany is facing a shortage of benzathine benzylpenicillin, a vital injectable antibiotic. The drug treats chronic streptococcal infections, prevents rheumatic fever, and combats early-stage syphilis. The Federal Ministry of Health has now officially declared the supply problem.

The shortage was first flagged by manufacturers last September. The antibiotic, part of the beta-lactam class, works by breaking down bacterial cell walls. It is widely used for long-term infections in children, adolescents, and adults.

No single company produces benzathine benzylpenicillin, as it is a generic drug. Key suppliers include Jodas Expoim Pvt. Ltd. and Lavina Pharmaceuticals in India, Pfizer’s Panidure LA 12, Spain’s Laboratorio Reig Jofre (Benzetacil), and France’s Delbert Pharma (Extencilline). To ease the crisis, regulators will temporarily relax approval rules for imported alternatives. However, the problem extends beyond this drug. Other essential antibiotics—cefuroxime, clindamycin, cotrimoxazole, and erythromycin—are also in short supply.

The shortage has forced Germany to seek faster access to foreign supplies. Authorities aim to restore stock levels by loosening import restrictions. Until then, patients relying on these antibiotics may face delays in treatment.